<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...

    Phio Pharmaceuticals is focused on developing t...

    Filing Type:    PU
    Achieve Life Sciences, Inc.

    Achieve Life Sciences, Inc.

    Achieve is a specialty pharmaceutical company committed to advancing cytisinicline...

    Achieve is a specialty pharmaceutical company c...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    Exelixis, Inc.

    Exelixis, Inc.

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...

    Filing Type:    PU
    NovoCure Limited

    NovoCure Limited

    Novocure is a global oncology company working to extend survival in some of the mo...

    Novocure is a global oncology company working t...

    Filing Type:    PU
    Allogene Therapeutics, Inc.

    Allogene Therapeutics, Inc.

    Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...

    Allogene Therapeutics is a clinical stage biote...

    Filing Type:    PU
    Gritstone Oncology, Inc.

    Gritstone Oncology, Inc.

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...

    Gritstone Oncology is developing tumor-specific...

    Filing Type:    PU
    Autolus Therapeutics plc

    Autolus Therapeutics plc

    Autolus is a clinical-stage, biopharmaceutical company, focused on the development...

    Autolus is a clinical-stage, biopharmaceutical ...

    Filing Type:    PU
    OncoSec Medical Incorporated

    OncoSec Medical Incorporated

    OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...

    OncoSec Medical Incorporated is a clinical-stag...

    Filing Type:    PU
    Heat Biologics, Inc.

    Heat Biologics, Inc.

    Heat Biologics a biopharmaceutical company that develops immunotherapies with the ...

    Heat Biologics a biopharmaceutical company that...

    Filing Type:    PU
    ADiTx Therapeutics, Inc

    ADiTx Therapeutics, Inc

    The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...

    The discovery of immunosuppressive (anti-reject...

    Filing Type:    RA
    Hutchison China MediTech Limited

    Hutchison China MediTech Limited

    Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...

    Hutchison China MediTech Limited, known as Chi-...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.